CINECA IRIS Institutional Research Information System

CAPPAGLI, VIRGINIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.976
AS - Asia 1.990
EU - Europa 1.922
SA - Sud America 325
Continente sconosciuto - Info sul continente non disponibili 138
AF - Africa 137
OC - Oceania 7
Totale 8.495
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.869
SG - Singapore 616
IT - Italia 591
CN - Cina 580
DE - Germania 385
HK - Hong Kong 304
SE - Svezia 278
BR - Brasile 262
VN - Vietnam 193
GB - Regno Unito 147
BG - Bulgaria 104
AT - Austria 92
FR - Francia 87
CA - Canada 66
CI - Costa d'Avorio 64
IN - India 61
JP - Giappone 55
RU - Federazione Russa 54
FI - Finlandia 47
TR - Turchia 41
SN - Senegal 28
BD - Bangladesh 27
NL - Olanda 26
AR - Argentina 23
MA - Marocco 21
MX - Messico 20
PL - Polonia 20
IQ - Iraq 15
ZA - Sudafrica 14
CZ - Repubblica Ceca 12
KR - Corea 11
PK - Pakistan 11
CO - Colombia 10
EC - Ecuador 10
ID - Indonesia 10
SA - Arabia Saudita 10
UZ - Uzbekistan 10
ES - Italia 9
GR - Grecia 9
PH - Filippine 9
CH - Svizzera 7
TW - Taiwan 7
UA - Ucraina 7
VE - Venezuela 7
EE - Estonia 6
RO - Romania 6
AU - Australia 5
DO - Repubblica Dominicana 5
IL - Israele 5
LT - Lituania 5
AL - Albania 4
AZ - Azerbaigian 4
CL - Cile 4
DK - Danimarca 4
IE - Irlanda 4
KE - Kenya 4
PT - Portogallo 4
PY - Paraguay 4
TT - Trinidad e Tobago 4
BE - Belgio 3
HN - Honduras 3
HU - Ungheria 3
IR - Iran 3
JO - Giordania 3
MY - Malesia 3
BY - Bielorussia 2
CR - Costa Rica 2
EG - Egitto 2
GT - Guatemala 2
LB - Libano 2
MC - Monaco 2
PA - Panama 2
PE - Perù 2
PS - Palestinian Territory 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
TN - Tunisia 2
UY - Uruguay 2
AE - Emirati Arabi Uniti 1
BB - Barbados 1
BH - Bahrain 1
BO - Bolivia 1
DZ - Algeria 1
ET - Etiopia 1
HR - Croazia 1
JM - Giamaica 1
KI - Kiribati 1
KZ - Kazakistan 1
LK - Sri Lanka 1
LV - Lettonia 1
MM - Myanmar 1
NZ - Nuova Zelanda 1
PR - Porto Rico 1
QA - Qatar 1
Totale 8.357
Salva come PNG Salva come JPEG
Città #
Ashburn 458
Dallas 380
Singapore 342
Hong Kong 299
San Jose 271
Chandler 245
Santa Clara 216
Fairfield 211
Milan 190
Houston 162
Woodbridge 156
Shanghai 120
New York 116
Beijing 106
Seattle 102
Sofia 102
Wilmington 85
Vienna 84
Los Angeles 82
Cambridge 73
Council Bluffs 72
Munich 71
Abidjan 64
Ho Chi Minh City 61
Ann Arbor 58
Boardman 55
Pisa 55
Princeton 54
Florence 50
London 50
Frankfurt am Main 45
Rome 44
Tokyo 41
Lauterbourg 40
Lawrence 40
Serra 36
Redmond 32
São Paulo 31
Medford 29
Dakar 28
Hanoi 25
Ottawa 24
Buffalo 23
Bremen 21
Atlanta 20
Redondo Beach 19
Dong Ket 18
Helsinki 18
Boulder 17
Denver 17
Hefei 17
Montreal 17
Tianjin 17
Redwood City 16
Casablanca 15
Des Moines 15
Istanbul 15
San Diego 15
Turku 15
Dearborn 14
Warsaw 14
Boston 13
Washington 13
Orem 12
Phoenix 12
Belo Horizonte 11
Chicago 11
Nuremberg 11
Amsterdam 10
Bengaluru 10
Chiesina Uzzanese 10
Fuzhou 10
Lancaster 10
Baghdad 9
Brooklyn 9
Columbus 9
Guangzhou 9
Haiphong 9
Johannesburg 9
Paris 9
Rio de Janeiro 9
Tashkent 9
Toronto 9
Ankara 8
Dhaka 8
Düsseldorf 8
Ogden 8
Poplar 8
Scandicci 8
Seoul 8
Brno 7
Hangzhou 7
Izmir 7
Lucca 7
Nanjing 7
Stockholm 7
Cascina 6
Chengdu 6
Fortaleza 6
Jiaxing 6
Totale 5.473
Salva come PNG Salva come JPEG
Nome #
Treatment of advanced thyroid cancer with targeted therapies: Ten years of experience 248
Medullary thyroid cancer treated with vandetanib: predictors of longer and durable response 246
Active surveillance in papillary thyroid microcarcinomas is feasible and safe: experience at one single Italian center 240
In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer 235
Targeted Therapy in Thyroid Cancer: State of the Art 226
Hypertension, nausea, anorexia and weight loss were significantly associated with better progression-free survival in patients with radioiodine-Refractory Differentiated Thyroid Carcinoma treated with Lenvatinib 218
Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations 215
Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life 212
Next generation sequencing revealed RET or RAS mutation in medullary thyroid cancer that were negative at sanger sequencing 206
Lenvatinib therapy in progressive, radioiodine-refractory, differentiated thyroid carcinoma: analysis of 74 cases followed in a single centre 201
GENETIC SCREENING OF RET CAN IDENTIFY NEW MUTATIONS EVEN AFTER 20 YEARS 197
Il carcinoma tiroideo: nuove prospettive terapeutiche. 195
AFTER 20 YEARS, RET GENETIC SCREENING STILL INDENTIFIES NEW GERMILINE AND SOMATIC MUTATIONS 190
Clinical, pathological and genetic features of anaplastic and poorly differentiated thyroid cancer: A single institute experience 184
Thyroid cancers: From surgery to current and future systemic therapies through their molecular identities 180
Fifty years after the first description, the MEN 2B syndrome diagnosisis still late: description of two recent cases 178
Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma 175
Central Neck Dissection Cannot Be Avoided In Medullary Thyroid Cancer (MTC) On The Basis Of Presurgical Serum Calcitonin (CT) 174
Lenvatinib treatment in the real clinical practice of progressive, radioiodine-refractory differentiated thyroid carcinoma: analysis of a big series followed in a single center 173
Systemic treatment of advanced, metastatic, medullary thyroid carcinoma 168
GENETIC LANDSCAPE OF SOMATIC MUTATIONS IN A LARGE COHORT OF SPORADIC MEDULLARY THYROID CARCINOMAS STUDIED BY NEXT GENERATION TARGETED SEQUENCING 165
MON-490 Calcitonin-Based Thyroidectomy Is a Safe Approach in Patients with Germline RET Mutation and Permits to Delay Surgery in Children 165
No difference in the outcome of metastatic thyroid cancer patients when using recombinant or endogenous TSH 164
New insights in the molecular signature of advanced medullary thyroid cancer: Evidence of a bad outcome of cases with double RET mutations 162
Impact of Advanced Age on the Clinical Presentation and Outcome of Sporadic Medullary Thyroid Carcinoma 159
Clinical evolution of sporadic medullary thyroid carcinoma with biochemical incomplete response after initial treatment 158
OR21-01 Pre-Operative Calcitonin Value as a Predictive Factor of Cancer Related Death in Sporadic Medullary Thyroid Carcinoma 158
Body Mass Index and Sporadic Medullary Thyroid Cancer: Insights from a Large Series 155
Long-Term Outcome of Patients with Low-Risk Differentiated Thyroid Cancer Treated with Total Thyroidectomy Alone 147
After 20 Years, RET genetic screening still identifies new germline and somatic mutations 147
Prevalence and Risk Factors of Developing Fistula or Organ Perforation in Patients Treated with Lenvatinib for Radioiodine-Refractory Thyroid Cancer 143
Cabozantinib: An orphan drug for thyroid cancer 140
Calcitonin receptor expression in medullary thyroid carcinoma 138
Ret mutated C-cells proliferate more rapidly than non-mutated neoplastic cells 135
RET Copy Number Alteration in Medullary Thyroid Cancer Is a Rare Event Correlated with RET Somatic Mutations and High Allelic Frequency 134
Redefining the prevalence of different clinical variants in MEN2A and their correlation with RET germline mutations: a single-center series and experience 131
Chylous effusions in advanced medullary thyroid cancer patients treated with selpercatinib 131
Thyroid cancer and COVID-19: experience at one single thyroid disease referral center 131
Proteinuria is a late-onset adverse event in patients treated with cabozantinib 129
The Usefulness of the International Grading System in the Management of Sporadic Medullary Thyroid Carcinoma 128
The Integrity of Tumor Capsule Identifies a Subgroup of Indolent Cases Not Only Among the Follicular (FVPTC) But Also in Classic Variant of Papillary Thyroid Cancer (CVPTC) 126
Active surveillance in differentiated thyroid cancer: a strategy applicable to all treatment categories response 122
MON-537 Primary Adrenal Insufficiency During Tyrosine Kinase Inhibitors Treatment in Advanced Thyroid Cancer Patients 120
Hypothesizing a role of ret hyperactivation on weight control in patients with type 2A multiple endocrine neoplasia (MEN2A) 117
Non thyroidal second primary malignancies in differentiated thyroid cancer patients: is the incidence increased comparing to the general population and could it be a radioiodine therapy consequence? 116
null 114
Clinical Management of a Patient with a Locally Recurrent Medullary Thyroid Cancer and Asymptomatic Slowly Progressing Distant Metastasis. 104
The timing of total thyroidectomy in RET gene mutation carriers could be personalized and safely planned on the basis of serum calcitonin: 18 Years experience at one single center 102
Hand-foot syndrome in sorafenib and lenvatinib treatment for advanced thyroid cancer 100
MULTIFOCALITY AND BILATERALITY IN MEDULLARY THYROID CANCER: BASIS FOR A PROOF-OF-CONCEPT SAFETY OF LOBECTOMY 97
Pre-surgical Value Of Basal Calcitonin Is Not Predictive Of Central Neck Compartment Metastases. 94
Predictive factors for central neck compartment lymphnodes metastases' in sporadic medullary thyroid cancer patients 92
null 58
Fifty Years after the First Description, MEN 2B Syndrome Diagnosis Is Still Late: Descriptions of Two Recent Cases 55
Genetic origin of multifocal sporadic medullary thyroid cancer and C-cell hyperplasia 51
Prevalence and genetics of "de novo" MEN2 syndromes 23
Comparison of pre-operative calcitonin, FNAC, and ultrasound risk stratification systems in patients with medullary thyroid carcinoma 23
Totale 8.495
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.000
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.000
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022484 0 15 7 25 100 66 16 20 31 27 43 134
2022/2023956 110 147 76 79 81 106 17 66 180 10 76 8
2023/2024621 59 70 94 55 86 109 22 10 3 5 33 75
2024/20251.702 16 67 22 101 182 150 168 89 162 226 186 333
2025/20262.741 200 398 307 280 288 200 348 130 173 217 100 100
2026/2027275 65 210 0 0 0 0 0 0 0 0 0 0
Totale 8.495